Medical
-
TFF Pharmaceuticals has announced topline safety results from a Phase 1 trial of its inhaled dry powder voriconazole, which is in development for the treatment of invasive pulmonary aspergillosis. The study demonstrated that doses as… Read more . . .
-
AstraZeneca said that complete results from the Phase 3 ETHOS trial of its Breztri Aerosphere (PT010) budesonide/glycopyrronium/formoterol fumarate MDI demonstrated that the triple combination reduced moderate or severe COPD exacerbations by 24% compared to glycopyrronium/formoterol… Read more . . .
-
Gilead Sciences Chairman and CEO Daniel O’Day has announced that the company has received FDA approval for a Phase 1 trial of inhaled remdesivir and will initiate the study within a week. Trials of the… Read more . . .
-
Vaccine developer Intravacc has published data from a preclinical study of an intranasal whooping cough vaccine demonstrating strong immune responses in mice. The intranasal vaccine also prevented colonization of the lung, trachea, and nose by… Read more . . .
-
Impel NeuroPharma has announced that the Phase 3 STOP 301 study of INP104 intranasal dihydroergotamine mesylate (DHE) for the treatment of acute migraine met its primary objectives, with 66.3% of patients experiencing pain relief and… Read more . . .
-
Novartis has announced results from the Phase 3b ARGON study of Enerzair Breezhaler (QVM149) indacaterol/glycopyrronium/mometasone for the treatment of uncontrolled asthma, with the data published in the journal Respiratory Medicine. The 24-week study met its primary… Read more . . .
-
Dutch vaccine maker Intravacc has announced that it is partnering with Wageningen Bioveterinary Research (WBVR) and Utrecht University on development of an intranasal Newcastle disease virus (NDV) vector vaccine for the prevention of COVID-19 in humans. The company said that… Read more . . .
-
Novus Therapeutics said that a Phase 2a clinical trial of its OP0201 intranasal surfactant MDI for the treatment of acute otitis media in infants and children failed to meet its primary endpoints of “resolution of… Read more . . .
-
Altimmune announced that the FDA has approved the company’s IND for a Phase 1/2 clinical trial of its T-COVID intranasal therapy for the treatment of COVID-19, with data expected to be available in the fourth… Read more . . .
-
Atossa Therapeutics announced that it has signed an agreement with Summit Biosciences for development and manufacturing of an intranasal formulation of Atossa’s AT-301 as a candidate for the treatment of mild COVID-19, and it plans… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany